Oxurion Announces Two Upcoming Presentations at The Macula
Leuven, BELGIUM, Boston, MA, US – JUNE 3, 2022 – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of...
Source: globenewswire.com
Page 8 - Highly Selective News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Highly Selective. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Highly Selective Today - Breaking & Trending Today
SELLAS Life Sciences Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the first acute myeloid leukemia (AML) patient has enrolled in the fifth dose level (22.
Source: pressreleasepoint.com
Investegate |RTW Venture Fund Ltd Announcements | RTW Venture Fund Ltd: New Investment in Third Harmonic Bio
Investegate announcements from RTW Venture Fund Ltd, New Investment in Third Harmonic Bio
Source: investegate.co.uk
Debiopharm Further Explores the Potential of its Potent | Highly Selective WEE1 Inhibitor Debio 0123 In Phase 1 Cancer Study
Dose escalation, monotherapy trial launched to access the safety and preliminary anti-tumor activity of Debio 0123 in the treatment of advanced solid ...
Source: zazoom.it
Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting
/PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will...
Source: prnewswire.com